Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background Oxyntomodulin has recently been found to decrease body-weight in obese humans and may be a potential anti-obesity therapy.Objective To determine whether oxyntomodulin alters energy expenditure, in addition to reducing energy intake, in 'free-living' overweight and obese volunteers.Design Randomized double-blind controlled cross-over trial.Setting Community and hospital-based.Participants Fifteen healthy overweight and obese men and women (age: 23-49 years, BMI: 25.1-39.0 kg/m(2)). All volunteers completed the study protocol.Interventions Four-day subcutaneous self-administration of pre-prandial oxyntomodulin, three times daily. Participants were advised to maintain their normal dietary and exercise regimen.Measurements (1) Energy expenditure, measured by indirect calorimetry and combined heart rate and movement monitoring; (2) energy intake, measured during a study meal.Results Oxyntomodulin administration reduced energy intake at the study meal by 128+/-29 kcal (P=0.0006) or 17.3+/-5.5% (P=0.0071), with no change in meal palatability. Oxyntomodulin did not alter resting energy expenditure; but increased activity-related energy expenditure by 143+/-109 kcal/day or 26.2+/-9.9% (P=0.0221); total energy expenditure by 9.4+/-4.8% (P=0.0454) and physical activity level by 9.5+/-4.6% (P=0.0495). A reduction in body weight of 0.5+/-0.2% was observed during the oxyntomodulin administration period (P=0.0232).Conclusion Oxyntomodulin increases energy expenditure while reducing energy intake resulting in negative energy balance. This data supports the role of oxyntomodulin as a potential anti-obesity therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Oxyntomodulin activates the glucagon receptor and GLP-1 receptor and promotes weight loss through elevated energy expenditure and decreased energy intake in humans (Wynne et al, 2005(Wynne et al, , 2006)).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Wynne et al, 2006
In the citing paper
“ACCORD, like the UKPDS, demonstrated that improved glucose control reduced microvascular complications126”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [126]
Citations
Cites
Obesity : Preventing and managing the global epidemic
Akram, D. S., Astrup, A. V., Atinmo, T., Boissin, J.-L., Bray, G. A., Carroll, K. N., Chitson, P., Chen, C., Dietz, W. H., Hill, J. O., et al. (2000) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 12,945
Prevalence of Overweight and Obesity Among US Children, Adolescents, and Adults, 1999-2002
Hedley, A. A. (2004) · JAMA · doi:10.1001/jama.291.23.2847 · Cited by 4,460
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Self-citationInhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604
Self-citationThe SCOFF questionnaire: Assessment of a new screening tool for eating disorders
Morgan, J. F., Reid, F., & Lacey, J. H. (1999) · BMJ · doi:10.1136/bmj.319.7223.1467 · Cited by 1,416
Role of Nonexercise Activity Thermogenesis in Resistance to Fat Gain in Humans
Levine, J. A., Eberhardt, N. L., & Jensen, M. D. (1999) · Science · doi:10.1126/science.283.5399.212 · Cited by 997
Reliability and validity of the combined heart rate and movement sensor Actiheart
Brage, S., Brage, N., Franks, P. W., Ekelund, U., & Wareham, N. J. (2005) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602118 · Cited by 667
Food Fails to Suppress Ghrelin Levels in Obese Humans
English, P. J. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.6.2984 · Cited by 534
Self-citationBrage, S., Brage, N., Franks, P. W., Ekelund, U., Wong, M.-Y., Andersen, L. B., Froberg, K., & Wareham, N. J. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00703.2003 · Cited by 473
Oxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans
Cohen, M. A., Ellis, S. M., Le Roux, C. W., Batterham, R. L., Park, A., Patterson, M., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030421 · Cited by 472
Self-citation
Cited by
Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00018.2018 · Cited by 5,286
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
“Administration of oxyntomodulin three times daily for 4 weeks to overweight or obese human subjects reduced food intake and induced weight loss (Wynne et al., 2005); oxyntomodulin also increased activity-related energy expenditure over a 4-day treatment period (Wynne et al., 2006).”
BackgroundPathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Gastrointestinal regulation of food intake
Cummings, D. E., & Overduin, J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30227 · Cited by 1,216
Gut hormones and the regulation of energy homeostasis
Murphy, K. G., & Bloom, S. R. (2006) · Nature · doi:10.1038/nature05484 · Cited by 778
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
The role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 614
Management of type 2 diabetes: new and future developments in treatment
Tahrani, A. A., Bailey, C. J., Del Prato, S., & Barnett, A. H. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60207-9 · Cited by 533
GLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510
“Oxyntomodulin modestly reduces food intake and increases activity-related energy expenditure leading to several kg of weight loss in short-term studies in people with overweight or obesity [114].”
BackgroundCentral Control of Body Weight and Appetite
Woods, S. C., & D'Alessio, D. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1630 · Cited by 458
Gut Hormones and Appetite Control
Wren, A. M., & Bloom, S. R. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.048 · Cited by 432
Self-citationThe New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
“When injected in either the brain or the periphery, acute and chronic administration of OXM reduces food intake and promotes weight loss in rodents (123–125) and humans (649, 650).”
BackgroundGlucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409
“An increase in activity-related energy expenditure was also noted in a separate study involving short-term treatment with the peptide (10).”
BackgroundSatiation, satiety and their effects on eating behaviour
Benelam, B. (2009) · Nutrition Bulletin · doi:10.1111/j.1467-3010.2009.01753.x · Cited by 340
Gastrointestinal Satiety Signals
Chaudhri, O. B., Salem, V., Murphy, K. G., & Bloom, S. R. (2008) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100506 · Cited by 334
Self-citationMichalakis, K., Mintziori, G., Kaprara, A., Tarlatzis, B. C., & Goulis, D. G. (2013) · Metabolism · doi:10.1016/j.metabol.2012.08.012 · Cited by 321
“energy expenditure [212].”
BackgroundThe role of gut hormones and the hypothalamus in appetite regulation
Suzuki, K., Simpson, K. A., Minnion, J. S., Shillito, J. C., & Bloom, S. R. (2010) · Endocrine Journal · doi:10.1507/endocrj.k10e-077 · Cited by 319
Self-citationFalkén, Y., Hellström, P. M., Holst, J. J., & Näslund, E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2876 · Cited by 315
Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.013 · Cited by 316
Ambery, P., Parker, V. E., Stumvoll, M., Posch, M. G., Heise, T., Plum-Moerschel, L., Tsai, L.-F., Robertson, D., Jain, M., Petrone, M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30726-8 · Cited by 298
Tan, T. M., Field, B. C. T., McCullough, K. A., Troke, R. C., Chambers, E. S., Salem, V., Gonzalez Maffe, J., Baynes, K. C. R., De Silva, A., Viardot, A., et al. (2013) · Diabetes · doi:10.2337/db12-0797 · Cited by 258
“Consistent with this hypothesis, the weak GcgR/GLP-1R coagonist oxyntomodulin is known to suppress appetite (11) and to increase EE, causing considerable weight loss in obese volunteers (12,13).”
BackgroundSelf-citationBoland, M. L., Laker, R. C., Mather, K., Nawrocki, A., Oldham, S., Boland, B. B., Lewis, H., Conway, J., Naylor, J., Guionaud, S., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0209-6 · Cited by 270
The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones
Meek, C. L., Lewis, H. B., Reimann, F., Gribble, F. M., & Park, A. J. (2016) · Peptides · doi:10.1016/j.peptides.2015.08.013 · Cited by 269
Self-citationPharmacotherapy of obesity: available medications and drugs under investigation.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248
Gut Peptides in the Regulation of Food Intake and Energy Homeostasis
Murphy, K. G., Dhillo, W. S., & Bloom, S. R. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0028 · Cited by 245
Self-citationHenderson, S. J., Konkar, A., Hornigold, D. C., Trevaskis, J. L., Jackson, R., Fritsch Fredin, M., Jansson‐Löfmark, R., Naylor, J., Rossi, A., Bednarek, M. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12735 · Cited by 240
“GLP-1 (7-37) HAEGT FTSDV SSYLE GQAAK EFIAW LVKGR G”
BackgroundSuzuki, K., Jayasena, C. N., & Bloom, S. R. (2012) · Experimental Diabetes Research · doi:10.1155/2012/824305 · Cited by 227
“Adiposity signals such as insulin and leptin are involved in the long-term energy homeostasis, and gut hormones such as PYY, GLP-1, PP, OXM, and ghrelin are implicated in the short-term regulation of meal ingestion [162–164].”
BackgroundSelf-citationRomero-Gómez, M., Lawitz, E., Shankar, R. R., Chaudhri, E., Liu, J., Lam, R. L. H., Kaufman, K. D., Engel, S. S., Bruzone, S. O., Coronel, M. J., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.013 · Cited by 220
Peripheral Mechanisms in Appetite Regulation
Camilleri, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.09.016 · Cited by 214
The obesity pipeline: current strategies in the development of anti-obesity drugs
Cooke, D., & Bloom, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2136 · Cited by 211
Self-citationThe role of gut hormones in the regulation of body weight and energy homeostasis
Karra, E., & Batterham, R. L. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.06.010 · Cited by 209
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
The L-cell in nutritional sensing and the regulation of appetite
Spreckley, E. (2015) · Frontiers in Nutrition · doi:10.3389/fnut.2015.00023 · Cited by 198
Drug therapy in obesity: a review of current and emerging treatments
Williams, D. M., Nawaz, A., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00816-y · Cited by 195
The regulation of food intake by the gut-brain axis: implications for obesity
Hussain, S. S., & Bloom, S. R. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.93 · Cited by 195
Self-citationAction and therapeutic potential of oxyntomodulin
Pocai, A. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.001 · Cited by 191
“Therefore the body weight-lowering effects of OXM likely involve suppression of food intake and an increase in energy expenditure (Figure 2) [30,38,51].”
BackgroundInfluentialThe Gut-Brain Axis, the Human Gut Microbiota and Their Integration in the Development of Obesity
Bliss, E. S., & Whiteside, E. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00900 · Cited by 186
“Since it has been reported to augment energy expenditure, it may also activate catecholaminergic and/or POMC neurons, as well as increase vagal activity at the site of brown fat, leading to increased thermogenesis (Dakin et al., 2002; Wynne et al., 2006; Pocai, 2014).”
BackgroundGLP-1/glucagon receptor co-agonism for treatment of obesity
Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4354-8 · Cited by 175
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM
Sadry, S. A., & Drucker, D. J. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.47 · Cited by 174
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
Bowels control brain: gut hormones and obesity
Field, B. C. T., Chaudhri, O. B., & Bloom, S. R. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.93 · Cited by 172
Self-citationThe role of the gut/brain axis in modulating food intake
Sam, A. H., Troke, R. C., Tan, T. M., & Bewick, G. A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.10.008 · Cited by 167
“As in rats, there is evidence that OXM may also increase energy expenditure in humans (Wynne et al., 2006).”
BackgroundPotential Hormone Mechanisms of Bariatric Surgery
Dimitriadis, G. K., Randeva, M. S., & Miras, A. D. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0276-5 · Cited by 167
The relationship between gut and adipose hormones, and reproduction
Comninos, A. N., Jayasena, C. N., & Dhillo, W. S. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmt033 · Cited by 167
“Peripheral oxyntomodulin reduces food intake in rats (Dakin et al., 2004) as well as in normal weight and obese humans (Cohen et al., 2003; Wynne et al., 2006).”
BackgroundTillner, J., Posch, M. G., Wagner, F., Teichert, L., Hijazi, Y., Einig, C., Keil, S., Haack, T., Wagner, M., Bossart, M., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13494 · Cited by 164
“The weight-loss effect of OXM is probably mediated by both components: GLP-1 agonism, which reduces energy intake, and GCR agonism, which increases energy expenditure.(22,28,29) Clinical studies in healthy normal-weight, overweight, or obese volunteers confirmed that subcutaneously administered OXM reduces body weight…”
BackgroundCoinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake
Cegla, J., Troke, R. C., Jones, B., Tharakan, G., Kenkre, J., McCullough, K. A., Lim, C. T., Parvizi, N., Hussein, M., Chambers, E. S., et al. (2014) · Diabetes · doi:10.2337/db14-0242 · Cited by 159
“These data are consistent with findings seen with acute infusion of OXM (16), suggesting that the anorectic and energy expenditure effects of OXM can be explained by costimulation of both the GLP-1 and glucagon receptors.”
BackgroundResultInfluentialSelf-citationThe intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Bany Bakar, R., Reimann, F., & Gribble, F. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00830-y · Cited by 144
“…in weight management and glucose homeostasis, which are starting to be exploited by use of dual GLP1 receptor and glucagon receptor agonism 190,191 ; given that no specific oxyntomodulin receptor has been identified, these effects are thought to be mediated by its dual action at the two…”
BackgroundZimmermann, T., Thomas, L., Baader-Pagler, T., Haebel, P., Simon, E., Reindl, W., Bajrami, B., Rist, W., Uphues, I., Drucker, D. J., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101633 · Cited by 149
“It has been shown conceptually that oxyntomodulin reduces bodyweight and food intake [22e24] and increases energy expenditure in humans [25].”
BackgroundPharmacological management of appetite expression in obesity
Halford, J. C. G., Boyland, E. J., Blundell, J. E., Kirkham, T. C., & Harrold, J. A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.19 · Cited by 156
Blüher, M., Rosenstock, J., Hoefler, J., Manuel, R., & Hennige, A. M. (2024) · Diabetologia · doi:10.1007/s00125-023-06053-9 · Cited by 138
“Oxyntomodulin has been shown to reduce bodyweight and food intake in rodents and humans [11, 12] and to increase energy expenditure in people with obesity [13], via activity at both receptors.”
BackgroundGut hormones: Implications for the treatment of obesity
Neary, M. T., & Batterham, R. L. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.005 · Cited by 158
“individuals (Wynne et al., 2006).”
Microbial regulation of GLP-1 and L-cell biology
Greiner, T. U., & Bäckhed, F. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.05.012 · Cited by 131
Unraveling oxyntomodulin, GLP1's enigmatic brother
Pocai, A. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0368 · Cited by 130
“The same authors using a similar experimental design and OXM administration demonstrated that 4-day s.c. self-administration of preprandial OXM (400 nmol) three times daily increased energy expenditure and decreased energy intake in overweight and obese volunteers (Wynne et al. 2006).”
BackgroundMethodInfluentialSustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment
Ashby, D. R., Ford, H. E., Wynne, K., Wren, A., Murphy, K. G., Busbridge, M., Brown, E. A., Taube, D. H., Ghatei, M. A., Tam, F. W. K., et al. (2009) · Kidney International · doi:10.1038/ki.2009.114 · Cited by 136
Self-citationNovel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angelidi, A. M., Belanger, M. J., Kokkinos, A., Koliaki, C. C., & Mantzoros, C. S. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab034 · Cited by 128
Lorenz, M., Evers, A., & Wagner, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.022 · Cited by 127
The future role of gut hormones in the treatment of obesity
Troke, R. C., Tan, T. M., & Bloom, S. R. (2014) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622313506730 · Cited by 125
“OXM has been shown to increase EE [Dakin et al. 2002; Wynne et al. 2006] which appears to be mediated via an increase in activity related EE.”
BackgroundSelf-citationAppetite Regulation: An Overview
Dhillo, W. S. (2007) · Thyroid · doi:10.1089/thy.2007.0018 · Cited by 126
“OXM also increases activity-related energy expenditure (121) in humans.”
Appetite Regulation: Hormones, Peptides, and Neurotransmitters and Their Role in Obesity
Miller, G. D. (2019) · American Journal of Lifestyle Medicine · doi:10.1177/1559827617716376 · Cited by 124
Central control of thermogenesis
Clapham, J. C. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.10.014 · Cited by 140
“Some, such as oxyntomodulin also have human validation (Wynne et al., 2006).”
Evers, S. S., Sandoval, D. A., & Seeley, R. J. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034423 · Cited by 117
Anti-obesity drugs and neural circuits of feeding
Adan, R. A. H., Vanderschuren, L. J. M. J., & ELAFLEUR, S. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.01.008 · Cited by 120
Gut hormone polyagonists for the treatment of type 2 diabetes
Brandt, S. J., Götz, A., Tschöp, M. H., & Müller, T. D. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.021 · Cited by 111
Behary, P., Tharakan, G., Alexiadou, K., Johnson, N., Wewer Albrechtsen, N. J., Kenkre, J., Cuenco, J., Hope, D., Anyiam, O., Choudhury, S., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0449 · Cited by 110
“GLP-1, OXM, and PYY are released from the L cells of the small intestine and colon, and their postprandial secretion is augmented several-fold after RYGB (4,5).”
BackgroundMethodSelf-citationMonteiro, M. P., & Batterham, R. L. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.053 · Cited by 105
Gut Hormones in Health and Obesity: The Upcoming Role of Short Chain Fatty Acids
Alhabeeb, H., AlFaiz, A., Kutbi, E., AlShahrani, D., Alsuhail, A., AlRajhi, S., Alotaibi, N., Alotaibi, K., AlAmri, S., Alghamdi, S., et al. (2021) · Nutrients · doi:10.3390/nu13020481 · Cited by 106
“This hormone is a dual agonist with its anorectic influence thought to be mainly mediated by GLP-1 receptor, while the weight-lowering effect of OXM is mediated by the glucagon receptor [70].”
BackgroundThe Glucagon Receptor Is Involved in Mediating the Body Weight‐Lowering Effects of Oxyntomodulin
Kosinski, J. R., Hubert, J., Carrington, P. E., Chicchi, G. G., Mu, J., Miller, C., Cao, J., Bianchi, E., Pessi, A., SinhaRoy, R., et al. (2012) · Obesity · doi:10.1038/oby.2012.67 · Cited by 106
“We tested OXM in lean Glp1r−/− mice replicating previous findings (4,6) which showed that acute treatment of OXM suppresses body weight in wild type but not in Glp1r−/− mice (data not shown).”
BackgroundMethodMaida, A., Lovshin, J. A., Baggio, L. L., & Drucker, D. J. (2008) · Endocrinology · doi:10.1210/en.2008-0336 · Cited by 103
“Although OXM inhibits food intake in fasted or fed rats (15–17), as well as in human subjects (19, 44), a separate receptor for OXM has not yet been identified.”
BackgroundMetabolic surgery and gut hormones – A review of bariatric entero-humoral modulation
Ashrafian, H., & le Roux, C. W. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.03.012 · Cited by 113
Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists
Evers, A., Haack, T., Lorenz, M., Bossart, M., Elvert, R., Henkel, B., Stengelin, S., Kurz, M., Glien, M., Dudda, A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00174 · Cited by 101
Valdecantos, M. P., Pardo, V., Ruiz, L., Castro‐Sánchez, L., Lanzón, B., Fernández‐Millán, E., García‐Monzón, C., Arroba, A. I., González‐Rodríguez, Á., Escrivá, F., et al. (2017) · Hepatology · doi:10.1002/hep.28962 · Cited by 100
“OXM reduces body weight in humans and rodents and improves glucose metabolism in mice (17) although the short half-life in circulation limits its therapeutic utility (18).”
BackgroundScott, W. R., & Batterham, R. L. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00038.2011 · Cited by 100
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Nogueiras, R., Nauck, M. A., & Tschöp, M. H. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00812-z · Cited by 102
Food preferences and underlying mechanisms after bariatric surgery
Behary, P., & Miras, A. D. (2015) · Proceedings of the Nutrition Society · doi:10.1017/s0029665115002074 · Cited by 98
Gut hormones and appetite control
Hameed, S., Dhillo, W., & Bloom, Sr. (2009) · Oral Diseases · doi:10.1111/j.1601-0825.2008.01492.x · Cited by 98
“OXM administered over 4 days to human volunteers has been shown to increase total energy expenditure by almost 10% (Wynne et al, 2006).”
Self-citationEmerging pharmacotherapies for obesity: A systematic review
Kokkorakis, M., Chakhtoura, M., Rhayem, C., Al Rifai, J., Ghezzawi, M., Valenzuela-Vallejo, L., & Mantzoros, C. S. (2025) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001045 · Cited by 102
Perakakis, N., Kokkinos, A., Peradze, N., Tentolouris, N., Ghaly, W., Pilitsi, E., Upadhyay, J., Alexandrou, A., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.153997 · Cited by 93
Central and peripheral control of food intake
Abdalla, M. M. I. (2017) · Endocrine Regulations · doi:10.1515/enr-2017-0006 · Cited by 92
Ullmer, C., Alvarez Sanchez, R., Sprecher, U., Raab, S., Mattei, P., Dehmlow, H., Sewing, S., Iglesias, A., Beauchamp, J., & Conde‐Knape, K. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12158 · Cited by 92
Adipose tissue, systematic inflammation, and neurodegenerative diseases
Migliolo, L., Boleti, A. P. D. A., Cardoso, P. H. D. O., Frihling, B. E. F., Silva, P. S. E., & de Moraes, L. F. R. N. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.343891 · Cited by 101
The Gut Hormones in Appetite Regulation
Suzuki, K., Jayasena, C. N., & Bloom, S. R. (2011) · Journal of Obesity · doi:10.1155/2011/528401 · Cited by 108
“After two weeks of prebiotic treatment, they observed increased gut microbiota fermentation, decreased appetite, and improved postprandial glucose responses.”
BackgroundSelf-citationBagger, J. I., Holst, J. J., Hartmann, B., Andersen, B., Knop, F. K., & Vilsbøll, T. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2335 · Cited by 88
“Glucagon [ 45, 19]% [ 47, 21]% Oxyntomodulin [ 20, 18]% AUC, min mmol/L 178 [160, 195] 160 [142, 177] 189 [171, 207] 163 [145, 180] 172 [155, 180] Saline [ 36, 1] [ 7, 30] [ 33, 4] [ 24, 13] GLP-1 [11, 48] [ 15, 22] [ 6, 31] Glucagon [ 44, 8] [ 35, 2] Oxyntomodulin [ 9, 27] ISR Peak, pmol/kg min 12 [11, 14] 6 [5, 7] 1…”
Tan, T., Behary, P., Tharakan, G., Minnion, J., Al-Najim, W., Albrechtsen, N. J. W., Holst, J. J., & Bloom, S. R. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00469 · Cited by 88
“Intravenous infusion or subcutaneous injectionof eachof the individual three hormones at slightly higher concentrations has been shown to cause modest reductions in ad libitum food intake in humans (8, 13, 14).”
BackgroundMethodInfluentialSelf-citationChaudhri, O. B., Parkinson, J. R. C., Kuo, Y.-T., Druce, M. R., Herlihy, A. H., Bell, J. D., Dhillo, W. S., Stanley, S. A., Ghatei, M. A., & Bloom, S. R. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.09.033 · Cited by 87
“Similarly, while there is evidence that OXM increases energy expenditure in rats [9] and activity-related energy expenditure in humans [19], agonists at the GLP-1 receptor have been found to reduce metabolic rate in mice and humans [11,24].”
BackgroundSelf-citationOxyntomodulin: actions and role in diabetes
Holst, J. J., Albrechtsen, N. J. W., Gabe, M. B. N., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.09.018 · Cited by 86
“In measurements of energy expenditure there was an overall increase in energy expenditure [68].”
The role of oxyntomodulin and peptide tyrosine–tyrosine (PYY) in appetite control
Wynne, K., & Bloom, S. R. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0318 · Cited by 96
Self-citationLeveraging the Gut to Treat Metabolic Disease
Gimeno, R. E., Briere, D. A., & Seeley, R. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.014 · Cited by 83
(2010) · PubMed
Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs
Druce, M. R., Minnion, J. S., Field, B. C. T., Patel, S. R., Shillito, J. C., Tilby, M., Beale, K. E. L., Murphy, K. G., Ghatei, M. A., & Bloom, S. R. (2009) · Endocrinology · doi:10.1210/en.2008-0828 · Cited by 84
Self-citationKoliaki, C. C., Liatis, S., Dalamaga, Μ., & Kokkinos, A. D. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00396-9 · Cited by 92
Gut Hormones and Energy Balance, The Future for Obesity Therapy?
Meiliana, A., & Wijaya, A. (2009) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v1i3.99 · Cited by 79
The Regulation of Peripheral Metabolism by Gut-Derived Hormones
Sun, E. W. L., Martin, A. M., Young, R. L., & Keating, D. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00754 · Cited by 71
Ambery, P. D., Klammt, S., Posch, M. G., Petrone, M., Pu, W., Rondinone, C., Jermutus, L., & Hirshberg, B. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13688 · Cited by 75
Bhat, V. K., Kerr, B. D., Flatt, P. R., & Gault, V. A. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.03.009 · Cited by 77
Kennett, G. A., & Clifton, P. G. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.07.020 · Cited by 82
CNS-targets in control of energy and glucose homeostasis
Kleinridders, A., Könner, A. C., & Brüning, J. C. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.10.006 · Cited by 84
Proglucagon-Derived Peptides as Therapeutics
Lafferty, R. A., O’Harte, F. P. M., Irwin, N., Gault, V. A., & Flatt, P. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.689678 · Cited by 71
Theilade, S., Christensen, M., Vilsbøll, T., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14270 · Cited by 82
“A specific receptor for oxyntomodulin has not been identified, but it binds to and activates both the GLP-1 receptor and the glucagon receptor.105 Effects of exogenous oxyntomodulin in humans include inhibition of gastric emptying, gastric and pancreatic exocrine secretion and food intake.106 Also, oxyntomodulin has b…”
BackgroundInfluentialBrain imaging studies of appetite in the context of obesity and the menstrual cycle
Van Vugt, D. A. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmp051 · Cited by 69
Can Gut Hormones Control Appetite and Prevent Obesity?
Chaudhri, O. B., Wynne, K., & Bloom, S. R. (2008) · Diabetes Care · doi:10.2337/dc08-s269 · Cited by 84
Self-citation
Metadata
- Authors
- Wynne, K., Park, A. J., Small, C. J., Meeran, K., Ghatei, M. A., Frost, G. S., & Bloom, S. R.
- Affiliations
- Hammersmith Hospital (GB)
- Corresponding author
- Bloom, S R
- Venue
- International Journal of Obesity
- Published
- 2006-04-18
- Volume
- 30
- Issue
- 12
- Pages
- 1729-1736
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- OpenAlex
- W2135978651
- Cited by
- 363
- References
- 32
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 14 · 2023: 22 · 2022: 15 · 2021: 22 · 2020: 18 · 2019: 14 · 2018: 21 · 2017: 15 · 2016: 20 · 2015: 16 · 2014: 21 · 2013: 32 · 2012: 24
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- International Journal of Obesity (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Medical Research Council
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- oxyntomodulin, energy expenditure, energy intake, obesity, overweight, obesity treatment, physical activity, weight loss, negative energy balance, GLP-1 receptor agonists
- MeSH terms
- Adult, Blood Pressure, Energy Intake, Double-Blind Method, Energy Metabolism, Female, Heart Rate, Humans, Injections, Subcutaneous, Insulin, Male, Middle Aged, Obesity, Self Administration, Body Mass Index, Cross-Over Studies, Anti-Obesity Agents, Overweight, Oxyntomodulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.